GlassScriptPhysician profile
Vadsana Smith
NPI 1669540357
$11,986.61
in general payments reported to CMS, 2019-2025
31 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $2,672 · 2023: $3,651 · 2024: $2,537 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,912 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,911.54 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,445.34 | 2022-2025 | |
| Janssen Biotech, INC. | $1,972.13 | 2022-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,392.06 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,123.08 | 2022-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $652.52 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $604.46 | 2022-2025 | |
| Celgene Corporation | $503.69 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $401.16 | 2023-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $292.59 | 2022-2024 | Ocaliva |
| Ardelyx, INC. | $267.18 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $259.79 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $246.16 | 2022-2024 | Dificid, Zinplava |
| Genzyme Corporation | $224.40 | 2022-2025 | |
| Celltrion USA INC. | $182.96 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $181.70 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $163.63 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $151.92 | 2022-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $145.89 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $145.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $138.10 | 2022 | |
| Phathom Pharmaceuticals, INC. | $82.78 | 2025 | Voquezna |
| Amgen INC. | $78.84 | 2022-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $58.90 | 2024-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $56.83 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $54.60 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $54.16 | 2022-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $26.66 | 2022 | |
| Merz Pharmaceuticals, LLC | $23.01 | 2025 | Xeomin |
| Alnylam Pharmaceuticals INC. | $20.56 | 2025 | Amvuttra |
| Scilex Pharmaceuticals INC. | $20.50 | 2025 | |
| Digestive Care, INC. | $15.88 | 2025 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vadsana Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.